The molecular mechanism of CDDP anticancer activity involves the transport of CDDP into the tumor cells through copper transporter 1 (CTR1), followed by chloride ligand(s) replacement by water molecules, resulting in the formation of cationic hydrate, such as cis-[Pt(NH3)2Cl(OH2)]+ and cis-[Pt(NH3)2(OH2)2]2+ [4,5]. The gene discussed is SLC31A1; the disease is neoplasm.